Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PF-07820435 |
| Synonyms | |
| Therapy Description |
PF-07820435 is a STING agonist that activates the STING pathway in immune cells, potentially leading to enhanced antitumor immune response (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PF-07820435 | PF07820435|PF 07820435 | STING1 Agonist 21 | PF-07820435 is a STING agonist that activates the STING pathway in immune cells, potentially leading to enhanced antitumor immune response (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06285097 | Phase I | PF-07820435 PF-06801591 + PF-07820435 | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors | Terminated | USA | 2 |